Results

RDF/XMLNTriplesTurtleShow queryShare ▶
SubjectPredicateObject
http://purl.uniprot.org/citations/33721375http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/33721375http://www.w3.org/2000/01/rdf-schema#comment"

Background

The programmed cell death protein 1 (PD-1) and its ligand 1 and 2 (PD-L1/PD-L2) regulate the immune system, and the checkpoint pathway can be exploited by malignant cells to evade anti-tumor immune response. Soluble forms (sPD-1/sPD-L1/sPD-L2) exist in the peripheral blood, but their biological and clinical significance is unclear.

Method

Time-resolved immunofluorometric assay (TRIFMA) and enzyme-linked immunosorbent assay (ELISA) were used to measure sPD-1, sPD-L1, and sPD-L2 levels in serum from 131 lymphoma patients and 22 healthy individuals.

Results

Patients had higher sPD-1 and sPD-L2 levels than healthy individuals. In diffuse large B-cell lymphoma, patients with high International Prognostic Index score had higher sPD-1 levels and sPD-L2 levels correlated with subtype according to cell of origin. Compared to other lymphoma types, follicular lymphoma displayed higher sPD-1 and lower sPD-L1 levels along with lower ligand/receptor ratios.

Conclusion

This is the first study to simultaneously characterize pretherapeutic sPD-1, sPD-L1, and sPD-L2 in a variety of lymphoma subtypes. The relation between higher sPD-1 levels and adverse prognostic factors suggests a possible biological role and potential clinical usefulness of sPD-1. Moreover, the reverse expression pattern in follicular lymphoma and T-cell lymphoma/leukemia may reflect biological information relevant for immunotherapy targeting the PD-1 pathway."xsd:string
http://purl.uniprot.org/citations/33721375http://purl.org/dc/terms/identifier"doi:10.1111/ejh.13621"xsd:string
http://purl.uniprot.org/citations/33721375http://purl.uniprot.org/core/author"Bjerre M."xsd:string
http://purl.uniprot.org/citations/33721375http://purl.uniprot.org/core/author"d'Amore F."xsd:string
http://purl.uniprot.org/citations/33721375http://purl.uniprot.org/core/author"Ludvigsen M."xsd:string
http://purl.uniprot.org/citations/33721375http://purl.uniprot.org/core/author"Kamper P."xsd:string
http://purl.uniprot.org/citations/33721375http://purl.uniprot.org/core/author"Enemark M.B."xsd:string
http://purl.uniprot.org/citations/33721375http://purl.uniprot.org/core/author"Monrad I."xsd:string
http://purl.uniprot.org/citations/33721375http://purl.uniprot.org/core/author"Mortensen J.B."xsd:string
http://purl.uniprot.org/citations/33721375http://purl.uniprot.org/core/date"2021"xsd:gYear
http://purl.uniprot.org/citations/33721375http://purl.uniprot.org/core/name"Eur J Haematol"xsd:string
http://purl.uniprot.org/citations/33721375http://purl.uniprot.org/core/pages"81-91"xsd:string
http://purl.uniprot.org/citations/33721375http://purl.uniprot.org/core/title"Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies."xsd:string
http://purl.uniprot.org/citations/33721375http://purl.uniprot.org/core/volume"107"xsd:string
http://purl.uniprot.org/citations/33721375http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/33721375
http://purl.uniprot.org/citations/33721375http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/33721375
http://purl.uniprot.org/uniprot/#_A0A0M3M0G7-mappedCitation-33721375http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/33721375
http://purl.uniprot.org/uniprot/#_A4GW21-mappedCitation-33721375http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/33721375
http://purl.uniprot.org/uniprot/#_Q2LC89-mappedCitation-33721375http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/33721375
http://purl.uniprot.org/uniprot/#_Q86TL7-mappedCitation-33721375http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/33721375
http://purl.uniprot.org/uniprot/#_Q0GN75-mappedCitation-33721375http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/33721375
http://purl.uniprot.org/uniprot/#_Q15116-mappedCitation-33721375http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/33721375
http://purl.uniprot.org/uniprot/#_Q9NZQ7-mappedCitation-33721375http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/33721375
http://purl.uniprot.org/uniprot/#_Q7Z5I0-mappedCitation-33721375http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/33721375
▶